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Abstract
Dicationic 2,6-diphenylpyrazines, aza-analogues and prodrugs were synthesized; evaluated for
DNA affinity, activity against Trypanosoma brucei rhodesiense (T. b. r.) and Plasmodium
falciparum (P. f.) in vitro, efficacy in T. b. r. STIB900 acute and T. b. brucei GVR35 CNS mouse
models. Most diamidines gave poly(dA-dT)2 ΔTm values greater than pentamidine, IC50 values:
T. b. r. (4.8 to 37 nM) and P. f. (10 to 52 nM). Most diamidines and prodrugs gave cures for
STIB900 model (11, 19a and 24b 4/4 cures); 12 3/4 cures for GVR35 model. Metabolic stability
half-life values for O-methylamidoxime prodrugs did not correlate with STIB900 results.
1. Introduction
Tropical protozoan diseases, such as malaria and human African trypanosomiasis (HAT),
affect millions of people in large parts of the world.1 Malaria caused by Plasmodium
falciparum (P. f.) leads to 665,000 deaths each year.2 HAT (or sleeping sickness), another
devastating disease, is caused by Trypanosoma brucei rhodesience (T. b. r.) and
Trypanosoma brucei gambiense (T. b. g.), which is eventually fatal without treatment. There
are below 10,000 reported cases and 30,000 estimated cases of HAT a year mostly in sub-
Saharan Africa.3, 4 HAT has two stages: an early stage in which the parasites reside and
proliferate in the hemolymphatic system and a second stage in which the parasites cross the
blood-brain barrier (BBB) and infect the central nervous system (CNS). 5 The drugs
currently in use against both malaria and HAT are far from satisfactory; most drugs suffer
from poor oral bioavailability and severe side effects. For example, the second stage HAT
drug melarsoprol causes a reactive encephalopathy which leads to death in 5% of treated
patients.6 Furthermore, for both diseases the cases of treatment failure because of drug
resistance have increased in recent years. For second stage HAT, there are only two drugs
melarsoprol and eflornithine available for monotherapy and NECT a combination therapy
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with niturtimox and eflornithine.7 Therefore, there is an urgent need for development of
more effective, orally available and less toxic drugs against these tropical protozoan
diseases.
Although numerous DNA binding aromatic diamidines exhibit potent antiprotozoal activity
against these tropical diseases, pentamidine 1 (Fig. 1) is the only one which has seen
significant clinical use in humans.8 Pentamidine has been used to treat first stage T. b. g.
HAT, antimony-resistant leishmaniasis, and Pneumocystis jiroveci pneumonia. Because the
amidine groups are protonated at physiological pH, pentamidine has low oral availability
and requires parenteral administration, which makes its clinical use difficult in remote
regions. Furamidine 2a (Fig. 1), a diphenyl furan diamidine analogue, is the active
metabolite of the di-O-methylamidoxime prodrug pafuramidine 2c (Fig. 1) which reached
phase III clinical trials against first-stage HAT and P. jiroveci pneumonia, and phase II
clinical trials against malaria.1, 5, 8, 9 Due to hepatic and renal toxicity of pafuramidine in
humans observed in an additional safety study paralleling the phase III trials, the further
development of pafuramidine has been terminated. Introduction of a nitrogen atom into one
or both of the terminal phenyl rings of furamidine resulted in aza-analogues of furamidine
3a and 4a (Fig. 1), which exihibited more potent in vivo activities against HAT than
pentamidine and furamidine.10, 11 The O-methylamidoxime prodrugs of azafuramidines 3c
and 4c (Fig. 1) were found to be quite effective in the second stage HAT GVR35 CNS
mouse model 5 and 3c was effective in a vervet monkey model of second stage HAT.12 As
yet, only very few compounds have shown good activity in the GVR35 CNS mouse model.
Since the aza-analogue 4c is better tolerated than 3c in toxicity studies in vervet monkeys,5
it is under further evaluation as a possible preclinical candidate for treatment of the second
stage HAT. Unexpectedly, the parent diamidine 4a also showed potent activity in the CNS
mouse model on intraperitoneal injection; therefore, 4a may have potential to become a
treatment option for second stage HAT.5
Due to the promising results from the furamidine series, a large number of furamidine
related diamidines have been synthesized.8, 13 Recently, we have described a series of linear
terphenyl diamidine 5 (Fig. 1) and their aza-analogues (e.g. 6), which showed significant
DNA minor groove binding affinity and low nanomolar antiprotozoal activity against T. b. r.
and P. f.14–16 The in vivo efficacy for three of those aza-analogues in the T. b. r. STIB900
acute mouse model is much superior to that of furamidine, and comparable to the
azafuramidines. Unfortunately, the di-amidoximes and di-O-methylamidoxime prodrugs of
the terphenyl dicationic analogues showed poor bioconversion and were not effective on
oral administration.14 In this study we have explored a series of novel curved dicationic 2,6-
diarylpyrazines, their aza-analogues and their prodrugs which are isomeric with their linear
2,5-pyrazines.14–16 Herein, we describe the synthesis, DNA binding affinity, in vitro
activities against T. b. r. and P. f. and in vivo activities in the T. b. r. STIB900 acute mouse
model and T. b. brucei GVR35 CNS mouse model for these curved 2,6-diarylpyrazines.
2. Chemistry
The synthesis of the parent dicationic 2,6-diphenylpyrazine 10 begins with Suzuki coupling
of 2,6-dichloropyrazine (7) with 4-cyanophenylboronic acid (8) to yield the
diphenylpyrazine di-nitrile 9 (Scheme 1).14–16 The di-nitrile 9 was converted to the
diamidine 10 by the action of lithium trimethylsilylamide [LiN(TMS)2] in THF. The di-
amidoxime prodrug 11 was obtained by reaction of the di-nitrile 9 with hydroxylamine and
followed by O-methylation with dimethylsulfate in the presences of lithium hydroxide to
yield the corresponding di-O-methylamidoxime prodrug 12. 10
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Employing the related Stille coupling process starting with 2,6-di(tri-n-
butylstannyl)pyrazine the symmetrical di-nitriles 14a and 14b were made in one step
(Scheme 2).17 The di-nitriles 14a–b were converted to the diamidines 15a–b using
LiN[TMS]2 as previously mentioned.
The dissymmetric mono-aza analogues 19a–b were made as outlined in Scheme 3. The
pyridyl rings are introduced in the first step by performing Stille coupling between 2-
chloro-6-(tri-n-butylstannyl)pyrazine and the appropriate bromocyanopyridines 16a–b.17
Subsequently, a Suzuki reaction between the 6-(pyridyl)-2-chloropyrazines 17a–b and 4-
cyanophenylboronic acid yields the dissymmetric di-nitriles 18a–b. The di-nitriles were
converted into the corresponding diamidines 19a–b, the amidoxines 20a,b and the O-
methylamidoximes 21a–b as discussed previously for Scheme 1.
The synthesis of the symmetrical di-aza analogues is presented in Scheme 4. It this case the
needed di-nitriles 22a–b are made directly by Stille coupling of the bromocyanopridines
16a–b with 2,6-di(tri-n-butylstannyl)pyrazine. The di-nitriles were converted into the
corresponding diamidines 23a–b, the amidoxines 24a–b and the O-methylamidoximes 25a–
b as discussed previously for Scheme 1.
3. Biology
The results for the evaluation of the dicationic 2,6-diarylpyrazine analogues and their
prodrugs against T. b. r. and P. f. and their DNA binding affinities are shown in Table 1. For
comparative purposes, the analogous data for pentamidine (1), furamidine (2a),
azafuramidines 3a, 4a and 2,5-diphenyl pyrazine diamidine (6) are also included in Table
1. 10, 16
The interaction of diamidines with nuclear and kinetoplast DNA has been shown to be an
important part of their mode of antiparasitic action.8f The ΔTm values of these dicationic
2,6-diphenylpyrazines and their aza-analogues range from high values of 15.1 °C to low
ones of 5.1 °C, as shown in Table 1. The parent diamidine 10 showed a ΔTm value of 15.1
°C, which is lower than that of furamidine (2a) (ΔTm = 25 °C) and higher than that of
pentamidine (1) (ΔTm = 12.6 °C). In comparison to 2a the ΔTm value of 10 is consistent
with its increased hydrophilic property as a result of the additional two nitrogen atoms in the
central pyrazine ring of 10. This result may further suggest that the hydrophobic component
is important for minor groove DNA binding. The ΔTm value (15.1°C) for 10 is higher than
that of the linear 2,5-isomer 6 (ΔTm = 8.0°C). One possible explanation for this result may
be that compound 10 presents an approximately crescent shape which more closely fits the
curvature of the DNA minor groove, similar to furamidine; and the linear isomer 6 needs
incorporation of a water molecule in the complex to simulate the curved structure of DNA
minor groove.20 The compounds 15a and 15b, methyl and fluorine substituted analogues,
showed much lower ΔTm values, which may be due to their twisted shape. Introduction of a
nitrogen atom meta to the amidine group in one or both of the phenyl rings in the parent
compound 10 leads to decreased DNA binding affinity: compound 19a with one nitrogen
resulted in a 2 °C decrease in ΔTm value and compound 23a with two nitrogen atoms gave a
ΔTm value with a 3.9 °C decrease. However, their corresponding ortho-isomers 19b and
23b showed a smaller influence on the DNA binding affinity: compound 19b, with one
nitrogen atom, showed the same ΔTm value as that of the parent compound 10 and
compound 23b, with two nitrogen atoms, showed a ΔTm value reduced by 3.0 °C. These
results are consistent with the effect of nitrogen substitution relationships found in the
previous study of the aza-analogues of furamdine (2a).10 It is also noteworthy that the
compounds which exhibit the higher ΔTm values showed the higher antitrypanosomal
activity whereas weaker binding compounds show lower activity (see below) which is
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consistent with previous observations that while a threshold level of binding appears
essential for activity a direct correlation between DNA affinity and in vitro activity is neither
expected nor found.8f A similar trend was not found for the antiplasmodial activity.
These 2,6-diarylpyrazine diamidines exhibited significant in vitro antitrypanosomal and
antiplasmodial activity at the low nanomolar level. The parent dicationic 2,6-
diphenylpyrazine 10 showed an IC50 value of 6 nM against T. b. r., comparable to that of
pentamidine and furamidine. The antiplasmodial activity of 10 (IC50 = 10 nM) is
approximately five-fold more active than pentamidine and slightly less active than
furamidine. The antiprotozoal activity of 10 is similar to that of the azafuramidine 3a.
Compared to the isomer 2,5-dicationic diphenylpyrazine 6, there are significant differences:
the 2,6-isomer 10 was three times more active than 2,5-isomer 6 against T. b. r.; conversely,
10 was 25-fold less potent than 6 against P. f. The 2,6-isomer 10 lost the good selectivity for
P. f. versus T. b. r. for which the 2,5-isomer 6 showed 45-fold selectivity for P. f., compared
to T. b. r. These differences may be due, in part, to the fact that the 2,6-diphenyl pyrazine
diamidine 10 is an approximately crescent shaped molecule which more closely fits the
curvature of the DNA minor groove, much similar to furamidine;8, 19 however, its dicationic
isomer 2,5-diphenylpyrazine 6 is a linear molecule which presumably requires the
incorporation of a water molecule into the recognition complex to simulate the curved
structure of DNA minor groove.20 The introduction of a methyl group or fluorine atom into
the meta-position to the amidine group on both of the phenyl rings yielded compounds 15a
and 15b which showed more than a sixty- and four-fold loss of their antiprotozoal activities
against T. b. r. and P. f., respectively. Compound 19a and 23a, in which a nitrogen atom has
been placed meta to the amidine group in one or both of the phenyl rings, showed a two- and
six-fold decrease in potency compared to the parent diamidine 10 against T. b. r. and a ten-
and six-fold decreased potency against P. f. The two analogues 19b and 23b, in which the
nitrogen atoms are ortho to the amidine, exhibited equivalent potency against T. b. r. and a
similar or eight-fold decrease in activity against P. f., compared to the parent compound 10.
It is noted that the compounds 19b and 23b in which the nitrogen atoms are ortho to the
amidine exhibited higher activity against T. b. r. than the corresponding meta-isomers 19a
and 23a. However, a similar trend was not found for P. f. activity. Ten potential di-
amidoxime and di-O-methylamidoxime prodrugs of the dicationic 2,6-diphenylpyrazine and
aza-analogues were prepared. As expected, these amidoximes and O-methylamidoxime
prodrugs showed low antiprotozoal activity when tested in vitro due to the absence of
metabolizing enzymes.10
Given the promising in vitro T. b. r. activity of these new diamidines, except the methyl
analogue 15a which showed only moderate antitrypanosomial activity, we have evaluated
them and their prodrugs in the stringent STIB900 acute mouse model for T. b. r. which
mimics first stage disease.5, 9, 18 Since the diamidines exhibit quite high pKa values (10–11)
and therefore unlikely to cross the intestinal barrier they were administered
intraperitoneally ; the prodrugs were designed to enhance oral bioavailability and hence
were given orally. The results are shown in Table 2 (diamidines) and Table 3 (prodrugs).
For comparative purposes Table 2 and Table 3 also contain in vivo data for the dicationic
analogues pentamidine (1), furamidine (2a), azafuramidines 3a and 4a, the dicationic 2,5-
diphenylpyrazine 6 and the prodrugs 2b, 2c, 3c and 4c in the same mouse model. 10, 14, 16, 23
On intraperitoneal dosing at 5 mg/kg all of the tested dications show a significant increase in
survival time for the treated animals compared to untreated controls. The parent compound
10 gave 3/4 cures at a dose of 5 mg/kg, which is superior to that of pentamidine (1) and
furamidine (2a) (1/4 cure), and is as effective as the azafuramidines 3a and 4a (3/4 cure).
The linear 2,5-isomer 6 was less effective and gave no cure but did show an increase in
mean survival time. The fluorine substituted analogue 15b gave also no cures in the in vivo
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model which is consistent with its lower in vitro activity against T. b. r. The four aza-
analogues 19a, 19b, 23a and 23b exhibited identical or better results to that for furamidine
at a dose of 5 mg/kg. The best result obtained was for compound 19a, which showed 4/4
cures at a dose of 5 mg/kg. It is noteworthy that although compounds 19a and 23a, in which
the nitrogen atom is meta to the amidine group, exhibited a significant loss of in vitro
potency against T. b. r. compared to their isomeric compounds 19b and 23b, in which the
nitrogen atom is ortho to the amidine, the in vivo efficacy of 19a (4/4 cure) and 23a (2/4
cure) was superior to the ortho isomers 19b (2/4 cure) and 23b (1/4 cure). This result may
be due to pharmacokinetic differences between the ortho and meta isomers and/or the
differential involvement of transporters. In general, the results for the aza-pyrazine
analogues are consistent with those observed for the aza-furamidine system.10
Although previous studies of di-amidoxime and di-O-methylamidoxime prodrugs of the
linear terphenyl diamidine analogues showed poor bioconversion and were not curative on
oral administration,14 all the di-amidoxime and di-O-methylamidoxime prodrugs of the
dicationic 2,6-diphenylpyrazine and aza-analogues showed activity when they were
administered orally to the mice during this study. In vitro metabolic stability studies using
mouse liver microsomes showed that di-O-methylamidoxime prodrugs were biotransformed
at different rates, with 12, 21b, and 25b showing shorter half-life than 21a and 25a (Table
4). However, this difference did not translate into activity in the STIB900 mouse model, as
the latter generally gave more cures, with the exception of 12 (Table 3). This disconnect is
likely due to a recent finding that intrahepatic binding and efflux of diamidines formed in
the hepatocytes, rather than enzymatic biotransformation of prodrugs, determined the
disposition of active diamidine metabolites.22 It should also be noted that there was a
marked interspecies difference in the metabolic stability of di-O-methylamidoxime
prodrugs, as liver microsomes derived from humans metabolized the prodrugs much faster
than those from mice (Table 4). This could be due to species differences in the enzyme
activity and expression level of CYP4F/cyp4f enzymes, which were shown to be responsible
for catalyzing the primary O-demethylation of the di-O-methylamidoxime pafuramidine in
the human liver and intestinal microsomes.23
Very interestingly, treatment with the amidoxime produgs 11 and 24b resulted in cures of all
mice at the oral dose of 25 mg/kg, superior to the corresponding O-methylamidoxime
prodrugs 12 (3/4 cure) and 25b (1/4 cure) at the same dosage. Both of the amidoximes 11
and 24b are more potent than the amidoxime prodrug 2b of furamidine which gave no cure
at an oral dose of 100 mg/kg (Table 3).24 These results do not parallel those observed in the
furamidine series, which showed that the O-methylamidoximes are more effective than the
amidoximes.10 The O-methylamidoxime prodrug 12 of the parent compound 10 gave 3/4
cures at the oral dose of 10 mg/kg. To evaluate the bioconversion of the di-amidoxime
prodrugs, mouse liver S9 fractions were used as they contain cytochrome b5 and cytochrome
b5 reductase, which are likely required to reduce amidoxime to amidine.25 All di-amidoxime
prodrugs examined in this study were efficiently metabolized (half-lives ranged from 2 to 51
min; Table 4), supporting their potential as prodrugs to generate active diamidine
metabolites in vivo, but failed to explain the superiority of oral 24b over other di-
amidoximes (except 11) in the STIB900 mouse model. As discussed above, this observation
underscores the role of intrahepatic binding and efflux from hepatocytes, rather than
bioconversion, in determining the disposition and activity of active diamidine metabolites in
vivo.
Given the potent in vivo activity found in the T. b. r. STIB900 acute mouse model 11 and 12
were selected for study in the T. b. brucei GVR35 mouse model for second stage disease.5 In
sharp contrast to the results found in the STIB900 model, 11 was not effective at a dosage of
100 mg/kg for five days in the GVR35 model providing no cures and only a modest increase
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(69 days) in survival time (Table 5). This shows that compound 11 is only able to remove
trypanosomes from the hemolymphatic compartment. However, at the same dosage 12 gave
2/5 cures. To achieve cures in the CNS mouse model drugs must cross the blood brain
barrier and reach trypanocidal levels in the CSF and CNS. These additional barriers often
result in CNS drug levels lower than that in blood. Hence, to attempt to compensate for this
circumstance where possible we further test with increased doses. When the dosing of 12
was extended to 10 days 3/4 cures were noted showing that this compound is penetrating
into the brain in sufficient concentration to cure CNS infection. The activity of 12 in the
GVR35 CNS model, with 2/5 mice cured at dosage of 100 mg/kg for five days compares
favorably with that for pafuramidine 2c which showed 3/5 cured at the same dosage with the
five day regimen. The efficacy of 12 is somewhat reduced from that of the O-
methylamidoxime prodrug 4c for treatment of second stage HAT which gave 5/5 cures at
the same dosage (Table 5).5 Nevertheless, prodrug 12 is one of only a very few compounds
which have shown good activity in this CNS model. The compounds 24b and 25a were also
selected for study in the T. b. brucei GVR35 CNS mouse model. Both compounds were not
curative at the oral dosage of 100 mg/kg for five days but they extended the survival time of
mice similarly to control mice treated with diminazine (at 40mg/kg ip single dose) which is
a diamidine curing only first stage disease. The results for the amidoxime and O-
methylamidoxime prodrugs of this series of dications provides stimulation for further
evaluation of their efficacy and toxicity.
4. Conclusions
A series of dicationic 2,6-diphenylpyrazines and aza analogues have been prepared which
exhibited DNA binding which is consistent with a role in their mode of action, showed
potent in vitro activity against both T. b. r. and P. f., and gave promising results on
intraperitoneal administration in the stringent T. b. r. STIB900 mouse model. The
diamidines 10 and 19a exhibited in vivo efficacy (3/4 or 4/4 cures at 5 mg/kg dosage, ip) in
the STIB900 model, superior to that of furamidine (2a), and comparable to or better than the
azafuramidines 3a and 4a. Eight of the ten prodrugs of the dicatonic 2,6-diphenylpyrazine
and aza-analogues showed good oral activity, giving cures in the STIB900 acute mouse
model. The potent O-methylamidoxime prodrug 12 also showed good in vivo oral efficacy
in the GVR35 second stage mouse model. This series of dicationic 2,6-diphenylpyrazine
analogues and their prodrugs merit further evaluation for treatment of both stages of HAT.
5. Experimental Section
5.1 Biology
5.1.1 Efficacy Studies—The in vitro assays13 with T. b. r. STIB 900 and P. f. K1 strain
as well as the efficacy studies in an acute mouse model for T. b. r. STIB 9005 were carried
out as previously reported. The studies in the T. b. brucei GVR35 mouse model for second
stage disease were performed as previously described.5 All protocols and procedures for the
mouse models used in the current study were reviewed and approved by the local veterinary
authorities of Canton Basel-Stadt, Switzerland. The data was generated at the time the
determination of survival was still accepted by the authorities.
5.1.2 Tm Measurements—Thermal melting experiments were conducted with a Cary
300 spectrophotometer. Cuvettes for the experiment were mounted in a thermal block and
the solution temperatures monitored by a thermistor in the reference cuvette. Temperatures
were maintained under computer control and increased at 0.5 °C/min. The experiments were
conducted in 1 cm path length quartz curvettes in CAC 10 buffer (cacodylic acid 10mM,
EDTA 1mM, NaCl 100mM with NaOH added to give pH = 7.0). The concentrations of
DNA were determined by measuring its absorbance at 260 nm. A ratio of 0.3 moles
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compound per mole of DNA was used for the complex and DNA alone was used as a
control.14 ΔTm values were determined by the peak in first derivative curves (dA/dT).26
5.1.3 In vitro metabolic stability assays—The procedures used were similar to a
reported method.23a Substrate stock solutions were prepared in DMSO. DMSO content was
kept at 0.5% (v/v) in final incubations. Incubation mixtures (final volume 0.25 ml) consisted
of 10 μM substrate and 0.5 mg/ml pooled liver microsomes from human or mouse
(XenoTech, Lenexa, KS) for O-methylamidoxime prodrugs, or liver S9 fraction from mouse
for amidoxime prodrugs. Reactions were carried out in 100 mM phosphate buffer (pH 7.4)
containing 3.3 mM MgCl2. Mouse liver S9 fractions were prepared from male Swiss
Webster mice (25–30 g) as previously reported. 27 Briefly, four volumes of 0.25 M sucrose
containing 0.1 M KCl and 1 mM EDTA was added to mouse liver and homogenized on ice
with a sonic dismembrator (Fisher Scientific, Fair Lawn, NJ). The homogenate was
centrifuged at 9,000×g for 20 min at 4°C and then the supernatant fraction (S9 fraction) was
collected and aliquoted before storing at −78°C. After a 5-min pre-equilibration period at
37°C, the metabolic stability reactions (in triplicate) were initiated by adding the cofactor (1
mM β-NADPH for microsomal incubations or a cocktail of 1 mM β-NADPH, 1 mM NADH,
and 3.3 mM UDPGA for incubations with S9 fractions) and kept at 37°C. Aliquots (100 μl)
of the reaction mixtures were removed at 0, 15, 30, and 60 min and individually mixed with
100 μl of ice-cold acetonitrile. The mixtures were vortex-mixed, and precipitated protein
was removed by centrifugation at 1,400×g for 15 min. The supernatant fractions were
analyzed immediately by HPLC/UV. 23a In vitro half-lives were obtained using the one-
phase exponential decay model with plateau set at zero (GraphPad Prism® 5.0, San Diego,
CA).
5.2 Chemistry
5.2.1 General materials and methods—Melting points were determined on a Mel-
Temp 3.0 melting point apparatus, and are uncorrected. TLC analysis was carried out on
silica gel 60 F254 precoated aluminum sheets using UV light for detection. 1H and 13C
NMR spectra were recorded on a Varian Unity Plus 300 MHz or Bruker 400 MHz
spectrometer using indicated solvents. Mass spectra was obtained from the Georgia State
University Mass Spectrometry Laboratory, Atlanta, GA. Elemental analysis were performed
by Atlantic Microlab Inc., Norcross, GA, and are within ±0.4 of the theoretical values. The
compounds reported as salts frequently analyzed correctly for fractional moles of water and/
or other solvents; in each case 1H NMR spectra was consistent with the analysis. All
chemicals and solvents were purchased from Aldrich Chemical Co., VWR International, or
Combi-Blocks, Inc.
5.2.2 2,6-Di-(4′-cyanophenyl)pyrazine (9)—To a stirred solution of 2,6-
dichloropyrazine (7, 2.0 g, 13.4 mmol) in toluene (56 mL) under nitrogen atmosphere at 80
°C was added 27 mL of 2 M aqueous solution of Na2CO3 followed by 4-
cyanophenylboronic acid 8 (4.34 g, 29.5 mmol) in 30 mL of methanol. After 30 minutes,
tetrakis(triphenylphosphine) palladium (1.34 g, 1.16 mmol) was added to the reaction
mixture. The reaction mixture was stirred overnight at 80 °C. After cooling to room
temperature, water was added to the mixture. The solution was filtered, and the precipitate
was washed with water and MeOH. The crude product was purified by recrystallization to
afford the title compound 9 (2.92 g, 77% yield); mp 298.5–299 °C. 1H NMR (DMSO-d6): δ
8.04 (d, J = 8.1 Hz, 4H), 8.47 (d, J = 8.1 Hz, 4H), 9.41 (s, 2H). 13C NMR (DMSO-d6): δ
148.8, 142.1, 139.9, 133.0, 127.7, 118.6, 112.6. MS: m/z 282 (M+). Anal. Calc. for
C18H10N4: C, 76.58; H, 3.57; N, 19.85. Found: C, 76.33; H, 3.55; N, 19.76.
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5.2.3 2,6-Di-(4′-amidinophenyl)pyrazine hydrochloride (10)—The above dinitrile 9
(0.14 g, 0.48 mmol), suspended in freshly distilled THF (4 mL), was treated with lithium
trimethylsilylamide (1 M solution in THF, 2.5 mL, 2.5 mmol), and the reaction was allowed
to stir overnight. The reaction mixture was then cooled to 0 °C and to which was added HCl
saturated ethanol (3 mL), whereupon a precipitate started forming. The mixture was allowed
to stir overnight, after which it was diluted with ether, and the precipitate was filtered. The
diamidine was purified by neutralization with 1 N NaOH followed by filtration of the
resultant solid and washing with water. Finally, the free base was stirred with ethanolic HCl
overnight and diluted with ether, and the solid formed was filtered and dried to give the
diamidine salt 10 (0.14 g, 76% yield); mp >300 °C. 1H NMR (DMSO-d6): δ 8.05 (d, J = 7.6
Hz, 4H), 8.53 (d, J = 7.6 Hz, 4H), 9.31 (s, 4H), 9.48 (s, 2H), 9.57 (s, 4H). 13C NMR
(DMSO-d6): δ 165.1, 149.1, 141.6, 140.5, 129.0, 128.9, 127.2. Anal. Calc. for
C18H16N6-2.0HCl-2.3H2O: C, 50.19; H, 5.29; N, 19.51. Found: C, 50.31; H, 4.92; N, 19.18.
5.2.4 2,6-Di-(4′-N-hydroxyamidinophenyl)pyrazine hydrochloride (11)—A
mixture of hydroxylamine hydrochloride (4.9 g, 70.8 mmol) in anhydrous DMSO (60 mL)
was cooled to 5 °C under nitrogen. Potassium tert-butoxide (7.95 g, 70.8 mmol) was added
in portions and the mixture was stirred for 30 minutes. To this mixture was added the above
dinitrile 9 (1.0 g, 3.54 mmol) and the mixture was stirred overnight. The reaction mixture
was poured slowly into a beaker with ice water and stirred for 15 minutes. The white
precipitate was filtered and washed with water to afford the free base of 11. The free base
was stirred with ethanolic HCl overnight and diluted with ether, and the precipitate which
formed was collected by filtration to give the title compound HCl salt 11 in 87% yield; mp
>300 °C. 1H NMR (DMSO-d6): δ 3.86 (s, 6H), 4.64 (s, 2H), 7.96 (d, J = 8.4 Hz, 4H), 8.51
(d, J = 8.4 Hz, 4H), 9.25 (s, 4H), 9.43 (s, 2H), 11.42 (s, 2H), 13.13 (s, 2H). 13C NMR
(DMSO-d6): δ 158.8, 149.1, 141.8, 140.0, 128.9, 127.3, 126.7. Anal. Calc. for
C18H16N6O2-2.2HCl-2.0H2O: C, 46.53; H, 4.82; N, 18.09. Found: C, 46.59; H, 4.45; N,
17.80.
5.2.5 2,6-Di-(4′-N-methoxyamidinophenyl)pyrazine hydrochloride (12)—A
solution of lithium hydroxide monohydrate (0.24 g, 5.74 mmol) in water (4 mL) was added
dropwise to the mixture of the free base of the above di-amidoxime 11 (0.43 g, 1.44 mmol)
in DMF (26 mL) at room temperature. The reaction mixture was stirred for 30 minutes at
room temperature. Dimethylsulfate (0.45 g, 3.59 mmol) was added to the reaction mixture
and the mixture was stirred at room temperature overnight. The reaction mixture was poured
slowly into a beaker with ice water and stirred for 15 minutes. The precipitate was filtered
and washed with water to afford the free base of 12. The free base was stirred with ethanolic
HCl overnight and diluted with ether, and the precipitate which formed was collected by
filtration to give the title compound 12 in 58% yield; mp 244–246 °C. 1H NMR (DMSO-d6):
δ 3.49 (s, 8H), 3.83 (s, 6H), 7.90 (d, J = 8.4 Hz, 4H), 8.38 (d, J = 8.4 Hz, 4H), 9.33 (s,
2H). 13C NMR (DMSO-d6): δ 156.7, 149.2, 141.6, 139.3, 128.5, 128.2, 127.1, 63.1. Anal.
Calc. for C20H20N6O2-2.0HCl-1.5H2O: C, 50.43; H, 5.29; N, 17.64. Found: C, 50.28; H,
5.17; N, 17.46.
5.2.6 2,6-Di-(4′-amidino-2′-methylphenyl)pyrazine hydrochloride (15a)—A
solution of 2,6-di(tri-n-butylstannyl)pyrazine (77% purity)17 (4.04 g, 4.68 mmol), 4-
bromo-3-methylbenzonitrile 13a (2.02 g, 10.30 mmol), tetrakis(triphenylphosphine)
palladium (0.56 g, 0.56 mmol) in degassed xylene (80 mL) was heated at 120 °C under
nitrogen atmosphere for 24 h. After cooling to room temperature, the mixture was filtered
and the precipitate was washed with xylene and ether. The crude product was purified by
recrystallization (DMF) to afford compound 14a in 62% yield [mp 239–141 °C (dec). 1H
NMR (DMSO-d6): δ 2.43 (s, 6H), 7.74 (d, J = 8.1 Hz, 2H), 7.83 (d, J = 8.1 Hz, 2H), 7.89 (s,
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2H), 8.95 (s, 2H). 13C NMR (DMSO-d6): δ 151.8, 143.5, 140.8, 137.8, 134.4, 131.0, 129.9,
118.5, 111.8, 19.8] and it was used directly in the next step without further characterization.
The same procedure described for the preparation of 10 was used starting with the above
dinitrile 14a; 52% yield; mp 250–252 °C (dec). 1H NMR (DMSO-d6): δ 2.46 (s, 6H), 7.80
(d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.89 (s, 2H), 8.98 (s, 2H), 9.32 (s, 4H), 9.52 (s,
4H). 13C NMR (DMSO-d6): δ 165.2, 152.1, 143.4, 141.2, 137.1, 130.6, 130.6, 128.6, 125.9,
20.2. Anal. Calc. for C20H20N6-2.5HCl-1.0H2O: C, 52.96; H, 5.44; N, 18.53. Found: C,
52.96; H, 5.31; N, 18.26.
5.2.7 2,6-Di-(4′-amidino-2′-fluorophenyl)pyrazine hydrochloride (15b)—The
same procedure described above for the preparation of 14a was used starting with 4-
bromo-3-fluorobenzonitrile 13b; to give 14b 62% yield [mp >300 °C. 1H NMR (DMSO-d6):
δ 8.12–8.16 (m, 2H), 8.37 (d, J = 8.4 Hz, 2H), 8.49 (d, J = 10.4 Hz, 2H), 9.48 (s, 2H).
HRMS: m/z 319.0800 (M+1) (calculated for C18H9N4F2, 319.0795)] and it was used
directly in the next step without further characterization.
The same procedure described for the preparation of 10 was used starting with the above
dinitrile 14b; 60% yield; mp >300 °C. 1H NMR (DMSO-d6): δ 7.89–7.92 (m, 2H), 8.37 (d, J
= 8.4 Hz, 2H), 8.44 (d, J = 12.4 Hz, 2H), 9.46 (s, 4H), 9.49 (s, 2H), 9.63 (s, 4H). 13C NMR
(DMSO-d6): δ 161.9, 159.2 (d, J = 248.2 Hz), 147.9 (d, J = 2.3 Hz), 142.0, 141.6 (d, J = 8.6
Hz), 130.7, 122.8 (d, J = 2.9 Hz), 118.3 (d, J = 13.7 Hz), 114.4 (d, J = 23.5 Hz). HRMS: m/z
353.1311 (M+1) (calculated for C18H15N6F2, 353.1326). Anal. Calc. for
C18H14F2N6-2.0HCl-1.3H2O: C, 48.18; H, 4.18; N, 18.73. Found: C, 48.37; H, 4.11; N,
18.67.
5.2.8 2-Chloro-6-(5′-cyanopyridin-2′-yl)pyrazine (17a)—A solution of 2-chloro-6-
(tri-n-butylstannyl)pyrazine17 (3.62 g, 9.0 mmol), 2-bromo-5-cyanopyridine 16a (1.67 g, 9.0
mmol), tetrakis(triphenylphosphine) palladium (0.52 g, 0.45 mmol) in degassed xylene (20
mL) was heated at 120 °C under nitrogen atmosphere overnight. After cooling to room
temperature, the mixture was filtered. Most of the solvent was removed under reduced
pressure; the precipitate which formed was filtered and washed with xylene and ether. The
crude product was purified by column chromatography on silica gel (eluent hexane/ethyl
acetate (5/1)) to give the title compound 17a in 67% yield; mp 148–150 °C. 1H NMR
(DMSO-d6): δ 8.41 (d, J = 8.4 Hz, 1H), 8.51 (dd, J = 2.0, 8.4 Hz, 1H), 8.97 (s, 1H), 9.20 (d,
J = 2.0 Hz, 1H), 9.51 (s, 1H). 13C NMR (DMSO-d6): δ 154.9, 152.6, 148.5, 147.9, 145.7,
141.7, 141.0, 121.2, 116.7, 110.1. Anal. Calc. for C10H5ClN4: C, 55.44; H, 2.33; N, 25.86.
Found: C, 55.55; H, 2.28; N, 25.83.
5.2.9 2-(4′-cyanophenyl)-6-(5′-cyanopyridin-2′-yl)pyrazine (18a)—The same
procedure described for 2,6-di-(4′-cyanophenyl)pyrazine 9 was used by employing 2-
chloro-6-(5′-cyanopyridin-2′-yl)pyrazine 17a and 4-cyanophenylboronic acid 8 to furnish
the compound 18a in 71% yield; mp 293–295 °C. 1H NMR (DMSO-d6): ): δ 8.04 (d, J = 8.4
Hz, 2H), 8.50 (d, J = 8.4 Hz, 2H), 8.53 (dd, J = 2.0, 8.4 Hz, 1H), 8.71 (d, J = 8.4 Hz, 1H),
9.19 (d, J = 2.0 Hz, 1H), 9.48 (s, 1H), 9.57 (s, 1H). HRMS: m/z 284.0930 (M+1) (calculated
for C17H10N5, 284.0936). Anal. Calc. for C17H9N5: C, 72.08; H, 3.20; N, 24.75. Found: C,
71.85; H, 3.17; N, 24.64.
5.2.10 2-(4′-amidinophenyl)-6-(5′-amidinopyridin-2′-yl)pyrazine hydrochloride (19a)
The same procedure described for the preparation of 10 was used starting with the above
dinitrile 18a; 90% yield; mp 296–298 °C (dec). 1H NMR (DMSO-d6): δ 8.05 (d, J = 8.4 Hz,
2H), 8.46 (dd, J = 2.0, 8.4 Hz, 1H), 8.58 (d, J = 8.4 Hz, 2H), 8.77 (d, J = 8.4 Hz, 1H), 9.17
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(d, J = 2.0 Hz, 1H), 9.27 (s, 2H), 9.40 (s, 2H), 9.56 (s, 2H), 9.56 (s, 1H), 9.62 (s, 1H), 9.73
(s, 2H). 13C NMR (DMSO-d6): δ 165.1, 163.7, 157.2, 149.0, 148.9, 148.2, 143.5, 142.1,
140.1, 137.9, 129.2, 128.9, 127.4, 125.2, 120.9. Anal. Calc. for C17H15N7-3.0HCl-1.7H2O:
C, 44.64; H, 4.72; N, 21.44. Found: C, 44.67; H, 4.52; N, 21.44.
5.2.11 2-(4′-N-hydroxyamidinophenyl)-6-(5′-N-hydroxyamidinopyridin-2′-
yl)pyrazine hydrochloride (20a)—The same procedure described for the preparation of
11 was used starting with the above dinitrile 18a; yield 89%; mp 283–285 °C (dec). 1H
NMR (DMSO-d6): δ 3.43 (s, 8H), 7.95 (d, J = 8.4 Hz, 2H), 8.36 (dd, J = 2.0, 8.4 Hz, 1H),
8.52 (d, J = 8.4 Hz, 2H), 8.68 (d, J = 8.4 Hz, 1H), 9.08 (d, J = 2.0 Hz, 1H), 9.47 (s, 1H), 9.57
(s, 1H). 13C NMR (DMSO-d6): δ 158.8, 156.9, 156.8, 149.0, 148.7, 148.2, 143.4, 142.0,
139.8, 137.9, 128.9, 127.5, 126.8, 122.9, 121.1. Anal. Calc. for
C17H15N7O2-3.0HCl-0.8H2O: C, 43.16; H, 4.18; N, 20.72. Found: C, 43.15; H, 4.22; N,
20.62.
5.2.12 2-(4′-N-methoxyamidinophenyl)-6-(5′-N-methoxyamidinopyridin-2′-
yl)pyrazine hydrochloride (21a)—The same procedure described for the preparation of
12 was used starting with the above compound 20a; 29% yield; mp 213–215 °C (dec). 1H
NMR (DMSO-d6): δ 3.43 (s, 8H), 3.83 (s, 3H), 3.85 (s, 3H), 7.92 (d, J = 8.4 Hz, 2H), 8.29
(dd, J = 2.0, 8.4 Hz, 1H), 8.39 (d, J = 8.4Hz, 2H), 8.57 (d, J = 8.4 Hz, 1H), 9.03 (d, J = 2.0
Hz, 1H), 9.38 (s, 1H), 9.52 (s, 1H). 13C NMR (DMSO-d6): δ 157.5, 155.1, 152.7, 149.0,
148.4, 147.7, 143.0, 141.8, 139.5, 136.6, 128.7, 127.4, 127.3, 126.1, 121.0, 63.4, 62.3. Anal.
Calc. for C19H19N7O2-3.0HCl-0.7H2O: C, 45.70; H, 4.72; N, 19.63. Found: C, 45.91; H,
4.67; N, 19.29.
5.2.13 2-Chloro-6-(2′-cyanopyridin-5′-yl)pyrazine (17b)—The same procedure
described for 2-chloro-6-(5′-cyanopyridin-2′-yl)pyrazine 17a was used by employing 2-
chloro-6-(tri-n-butylstannyl)pyrazine 17 and 2-bromo-5-cyanopyridine 16b to furnish the
title compound 17b in 52% yield; mp 149–151 °C. 1H NMR (DMSO-d6): δ 8.24 (d, J = 8.4
Hz, 1H), 8.71 (dd, J = 2.0, 8.4 Hz, 1H), 8.91 (s, 1H), 9.45 (d, J = 2.0 Hz, 1H), 9.46 (s,
1H). 13C NMR (DMSO-d6): δ 149.4, 148.1, 147.7, 144.7, 141.3, 136.0, 133.5, 133.4, 129.2,
117.3. Anal. Calc. for C10H5ClN4: C, 55.44; H, 2.33; N, 25.86. Found: C, 55.67; H, 2.30; N,
25.60.
5.2.14 2-(4′-amidinophenyl)-6-(2′-amidinopyridin-5′-yl)pyrazine hydrochloride
(19b)—The same procedure described for 2,6-di-(4′-cyanophenyl)pyrazine 9 was used by
employing 2-chloro-6-(2′-cyanopyridin-5′-yl)pyrazine 17b and 4-cyanophenylboronic acid 8
to furnish the compound 18b in 88% yield [mp 271–273 °C. 1H NMR (DMSO-d6): δ 8.06
(d, J = 8.4 Hz, 2H), 8.26 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 8.4 Hz, 2H), 8.90 (dd, J = 2.0, 8.4
Hz, 1H), 9.48 (s, 1H), 9.50 (s, 1H), 9.63 (d, J = 2.0Hz, 1H). 13C NMR (DMSO-d6): δ 149.5,
149.0, 147.0, 142.6, 142.4, 139.6, 135.9, 134.6, 133.3, 133.0, 129.2, 127.8, 118.6, 117.4,
112.7] and it was used directly in the next step without further characterization.
The same procedure described for the preparation of 10 was used starting with the above
dinitrile 18b; yield 87%; mp >300 °C. 1H NMR (DMSO-d6): δ 8.04 (d, J = 8.8 Hz, 2H),
8.52 (d, J = 8.4 Hz, 1H), 8.55 (d, J = 8.8 Hz, 2H), 9.02 (dd, J = 2.0, 8.4 Hz, 1H), 9.21 (s,
2H), 9.46 (s, 2H), 9.51 (s, 2H), 9.51 (s, 1H), 9.54 (s, 1H), 9.65 (d, J = 2.0 Hz, 1H), 9.70 (s,
2H). 13C NMR (DMSO-d6): δ 165.1, 161.6, 149.3, 148.1, 147.2, 144.7, 142.6, 142.4, 140.2,
136.4, 135.3, 129.3, 128.9, 127.4, 123.6. Anal. Calc. for C17H15N7-2.0HCl-1.55H2O: C,
48.83; H, 4.84; N, 23.44. Found: C, 49.15; H, 4.78; N, 23.07.
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yl)pyrazine hydrochloride (20b)—The same procedure described for the preparation of
11 was used starting with the above dinitrile 18b; yield 87%; mp 291–293 °C (dec). 1H
NMR (DMSO-d6): δ 3.44 (s, 4H), 7.95 (d, J = 8.4 Hz, 2H), 8.24 (d, J = 8.4 Hz, 1H), 8.53 (d,
J = 8.8 Hz, 2H), 8.87 (dd, J = 2.0, 8.4 Hz, 1H), 9.21 (s, 2H), 9.45 (s, 1H), 9.49 (s, 1H), 9.56
(d, J = 2.0 Hz, 1H), 11.01 (s, 1H), 11.20 (s, 1H). 13C NMR (DMSO-d6): δ 158.7, 154.7,
149.2, 147.9, 147.4, 145.0, 142.3, 142.1, 139.7, 136.0, 134.4, 128.9, 127.4, 126.8, 123.0.
Anal. Calc. for C17H15N7O2-2.0HCl-1.4H2O: C, 45.63; H, 4.46; N, 21.91. Found: C, 45.99;
H, 4.40; N, 21.56.
5.2.16 2-(4′-N-methoxyamidinophenyl)-6-(2′-N-methoxyamidinopyridin-5′-
yl)pyrazine hydrochloride (21b)—The same procedure described for the preparation of
12 was used starting with the above compound 20b; yield 37%; mp 160–162 °C (dec). 1H
NMR (DMSO-d6): δ 3.86 (s, 3H), 3.88 (s, 3H), 3.89 (s, 8H), 7.96 (d, J = 8.0 Hz, 2H), 8.10
(d, J = 8.4 Hz, 1H), 8.46 (d, J = 8.0 Hz, 2H), 8.87 (dd, J = 2.0, 8.4 Hz, 1H), 9.41 (s, 1H),
9.43 (s, 1H), 9.47 (d, J = 2.0 Hz, 1H). 13C NMR (DMSO-d6): δ 157.3, 150.7, 149.3, 148.3,
147.9, 147.2, 141.8, 141.7, 139.5, 135.5, 132.8, 128.7, 127.6, 127.2, 121.1, 63.4, 62.0. Anal.
Calc. for C19H19N7O2-2.0HCl-2.0H2O: C, 46.92; H, 5.18; N, 20.16. Found: C, 46.98; H,
5.09; N, 19.93.
5.2.17 2,6-Di-(5′-cyanopyridin-2′-yl)pyrazine (22a)—The same procedure described
for 2,6-di-(4′-cyano-2′-methylphenyl)pyrazine 14a was used by employing 2,6-di(tri-n-
butylstannyl)pyrazine and 2-bromo-5-cyanopyridine 16a to furnish the title compound 22a
in 58% yield; mp 264–266 °C (dec).1H NMR (DMSO-d6): δ 8.69 (dd, J = 2.1, 8.4 Hz, 2H),
8.80 (d, J = 8.4 Hz, 2H), 9.23 (s, 2H), 9.67 (d, J = 2.1 Hz, 2H). 13C NMR (DMSO-d6): δ
155.9, 152.6, 147.8, 143.8, 141.6, 121.4, 116.9, 110.0. Anal. Calc. for C16H8N6: C, 67.60;
H, 2.84; N, 29.56. Found: C, 67.41; H, 2.73; N, 29.31.
5.2.18 2,6-Di-(5′-amidinopyridin-2′-yl)pyrazine hydrochloride (23a)—The same
procedure described for the preparation of 10 was used starting with the above dinitrile 22a;
50% yield; mp 277–279 °C (dec). 1H NMR (DMSO-d6): δ 8.48 (dd, J = 2.4, 8.4 Hz, 2H),
8.86 (d, J = 8.1 Hz, 2H), 9.18 (d, J = 2.4 Hz, 2H), 9.41 (s, 4H), 9.72 (s, 2H), 9.74 (s,
4H). 13C NMR (DMSO-d6): δ 163.7, 156.9, 149.0, 148.1, 143.6, 138.0, 125.2, 121.1. Anal.
Calc. for C16H14N8-2.0HCl-2.5H2O: C, 44.05; H, 4.85; N, 25.68. Found: C, 44.08; H, 4.67;
N, 25.39.
5.2.19 2,6-Di-(5′-N-hydroxyamidinopyridin-2′-yl)pyrazine hydrochloride (24a)—
The same procedure described for the preparation of 11 was used starting with the above
dinitrile 22a in 97% yield; mp 274–276 °C (dec).1H NMR (DMSO-d6-D2O): δ 3.52 (s, 6H),
8.32 (dd, J = 2.0, 8.4 Hz, 2H), 8.74 (d, J = 8.4 Hz, 2H), 9.03 (d, J = 2.0 Hz, 2H), 9.65 (s,
2H), 11.08 (s, 2H). 13C NMR (DMSO-d6): δ 156.4, 156.2, 148.6, 148.1, 143.4, 137.6, 123.5,
121.2. Anal. Calc. for C16H14N8O2-2.0HCl-2.1H2O: C, 41.68; H, 4.42; N, 24.30. Found: C,
41.71; H, 4.30; N, 24.30.
5.2.20 2,6-Di-(5′-N-methoxyamidinopyridin-2′-yl)pyrazine hydrochloride (25a)—
The same procedure described for the preparation of 12 was used starting with the above
compound 24a; yield 58%; mp 216–218 °C (dec). 1H NMR (DMSO-d6): δ 3.82 (s, 6H),
4.00 (s, 6H), 6.70 (s, 2H), 8.27 (dd, J = 1.8, 8.4 Hz, 2H), 8.64 (d, J = 8.4 Hz, 2H), 9.04 (d, J
= 1.8 Hz, 2H), 9.61 (s, 2H). 13C NMR (DMSO-d6): δ 154.5, 151.4, 148.4, 147.4, 142.8,
135.9, 127.2, 121.1, 61.9. Anal. Calc. for C18H18N8O2-3.0HCl-2.3H2O: C, 40.85; H, 4.88;
N, 21.17. Found: C, 41.01; H, 4.89; N, 21.07.
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5.2.21 2,6-Di-(2′-cyanopyridin-5′-yl)pyrazine (22b)—The same procedure described
for 2,6-di-(4′-cyano-2′-methylphenyl)pyrazine 14a was used by employing 2,6-di(tri-n-
butylstannyl)pyrazine and 5-bromo-2-cyanopyridine 16b to furnish the title compound 22b;
70% yield; mp >300 °C. 1H NMR (DMSO-d6): δ 8.27 (d, J = 8.0 Hz, 2H), 8.94 (dd, J = 2.0,
8.0 Hz, 2H), 9.54 (s, 2H), 9.66 (d, J = 2.0 Hz, 2H). 13C NMR (DMSO-d6): δ149.6, 147.2,
143.0, 136.1, 134.4, 133.4, 129.2, 117.4. Anal. Calc. for C16H8N6: C, 67.60; H, 2.84; N,
29.56. Found: C, 67.34; H, 2.73; N, 29.28.
5.2.22 2,6-Di-(2′-amidinopyridin-5′-yl)pyrazine hydrochloride (23b)—The same
procedure described for the preparation of 10 was used starting with the above dinitrile 22b;
83% yield; mp 249–251 °C (dec). 1H NMR (DMSO-d6): δ 8.58 (d, J = 8.1 Hz, 2H), 9.06
(dd, J = 1.2, 8.1 Hz, 2H), 9.59 (s, 4H), 9.61 (s, 2H), 9.68 (d, J = 1.2 Hz, 2H), 9.78 (s,
4H). 13C NMR (DMSO-d6): δ 151.3, 147.9, 147.6, 147.3, 142.0, 135.6, 133.0, 121.5. Anal.
Calc. for C16H14N8-2.0HCl-1.4H2O: C, 46.14; H, 4.55; N, 26.91. Found: C, 46.42; H, 4.52;
N, 26.52.
5.2.23 2,6-Di-(2′-N-hydroxyamidinopyridin-5′-yl)pyrazine hydrochloride (24b)—
The same procedure described for the preparation of 11 was used starting with the above
dinitrile 22b; 69% yield; mp 280–282 °C (dec). 1H NMR (DMSO-d6): δ 8.40 (dd, J = 2.1,
8.4 Hz, 2H), 8.80 (d, J = 8.4 Hz, 2H), 8.82 (s, 2H), 9.10 (d, J = 2.1 Hz, 2H), 9.68 (s, 2H),
11.28 (s, 2H). 13C NMR (DMSO-d6): δ 155.0, 148.0, 147.6, 144.8, 142.7, 136.2, 134.4,
123.2. Anal. Calc. for C16H14N8O2-3.0HCl-0.75H2O: C, 40.61; H, 3.94; N, 23.68. Found:
C, 40.81; H, 4.18; N, 23.35.
5.2.24 2,6-Di-(2′-N-methoxyamidinopyridin-5′-yl)pyrazine hydrochloride (25b)
—The same procedure described for the preparation of 12 was used starting with the above
compound 24b; 50% yield; mp 89–91 °C. 1H NMR (DMSO-d6): δ 3.85 (s, 6H), 8.07 (d, J =
8.4 Hz, 2H), 8.72 (dd, J = 2.4, 8.4 Hz, 2H), 9.43 (s, 2H), 9.46 (d, J = 2.4 Hz, 2H). 13C NMR
(DMSO-d6): δ 150.1, 149.0, 148.3, 146.9, 141.5, 135.0, 131.8, 119.9, 61.2. Anal. Calc. for
C18H18N8O2-2.0HCl-0.7H2O: C, 46.60; H, 4.65; N, 24.15. Found: C, 46.80; H, 4.79; N,
23.95.
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Scheme 1. Reagents and conditions
(i) Pd(PPh3)4, Na2CO3, toluene, 80 °C; (ii) (a) LiN(TMS)2, THF; (b) HCl(gas), EtOH; (iii)
NH2OH-HCl, KOt-Bu, DMSO; (iv) LiOH, (CH3)2SO4, DMF.
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Scheme 2. Reagents and conditions
(i) 2,6-bis(tri-n-butylstannyl)pyrazine, Pd(PPh3)4, xylene, 120 °C; (ii) (a) LiN(TMS)2, THF;
(b) HCl(gas), EtOH.
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Regents and conditions: (i) 2-chloro-6-(tri-n-butylstannyl)pyrazine, Pd(PPh3)4, xylene, 120
°C; (ii) Pd(PPh3)4, Na2CO3, toluene, 80 °C; (iii) (a) LiN(TMS)2, THF; (b) HCl(gas), EtOH;
(iv) NH2OH-HCl, KOt-Bu, DMSO; (v) LiOH, (CH3)2SO4, DMF.
Hu et al. Page 18













Scheme 4. Reagents and conditions
(i) 2,6-bis(tri-n-butylstannyl)pyrazine, Pd(PPh3)4, xylene, 120 °C; (ii) (a) LiN(TMS)2, THF;
(b) HCl(gas), EtOH; (iii) NH2OH-HCl, KOt-Bu, DMSO; (iv) LiOH, (CH3)2SO4, DMF.
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Table 2
In vitro and in vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidines in the STIB900 mouse
model.a
Code T. b. r.
IC50(nM)
Dosage (ip, mg/kg) b Cures c Survival (days) d
1 2.2 20 2/4 >57.5
5 1/4 >38
2a 4.5 20 3/4 >57.75
5 1/4 >46
3a 6.5 20 4/4 >60
5 3/4 >54.5
4a 21 20 4/4 >60
5 3/4 >49.5
6 18 5 0/4 36.5
10 5.8 5 3/4 >53.5
15a 462 / / /
15b 27 5 0/4 >41
19a 14 5 4/4 >60
19b 6 5 2/4 >60
23a 37 5 2/4 >53.75
23b 4.8 5 1/4 >36.5
a
See Refs. 5 and 18 for details of STIB900 mouse model.
b
Daily dosage was administered for 4 days; ip, intraperitoneal.
c
Number of mice that survive and are parasite free for 60 days.
d
Average days of survival; untreated control expires between day 7 and 9 post-infection.
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Table 3
In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the STIB900 mouse model.a
Code Dosage (po, mg/kg)c Cures d Survival (days)e
2b(2a) 100 0/4 50
2c(2a) 25 4/4 >60
10 4/4 >60
3c(3a) 25 4/4 >60
4c(4a) 25 2/4 >42
11(10) 25 4/4 >60
10 0/4 22.5
12(10) 25 3/4 >53.5
10 3/4 >56.5
20a(19a) 25 2/4 >45.75
21a(19a) 25 3/4 >57.5
10 1/4 >49
20b(19b) 25 2/4 >50
21b(19b) 25 2/4 >50
24a(23a) 25 0/4 23.75
25a(23a) 25 2/4 >38.75
24b(23b) 25 4/4 >60
10 1/4 >33.75
25b(23b) 25 1/4 >43.25
a
See Refs. 5 and 18 for details of STIB900 mouse model.
b
Code for parent of prodrug in parenthesis.
c
Daily dosage was administered for 4 days.
d
Number of mice that survive and are parasite free for 60 days.
e
Average days of survival; untreated control expires between day 7 and 9 post-infection.
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Table 4
In vitro metabolic stability of 2,6-diarylpyrazine diamidine prodrugs
Code Mouse t1/2 (min)a Human t1/2 (min)a
2b 29 ± 10# NDb
2c 150 ± 10c 6.8 ± 2c
11 1.9 ± 0.1# ND
12 26 ± 6 8.6 ± 0.9
20a 30 ± 4# ND
21a 210 ± 100 7.6 ± 0.3
20b 36 ± 5# ND
21b 35 ± 6 6.5 ±1.2
24a 20 ± 0.4# ND
25a 200 ± 70 70 ± 23
24b 51 ± 1.4# ND
25b 59 ± 10 14 ± 6
#
Bis-amidoxime prodrugs were incubated with mouse liver S9 fraction, instead of liver microsomes.
a




Substrate concentration for 2c was 3 μM and its t1/2 was shown as mean and range of duplicate determinations.
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Table 5
In vivo anti-trypanosomal activity of 2,6-diarylpyrazine diamidine prodrugs in the GVR35 CNS mouse
model.a
Codeb Dosage (po, mg/kg)/no. of days administered No. of mice cured c MSDd
2ce(2a) 100/5 3/5 >167.8
3ce(3a) 100/5 5/5 >180
4ce(4a) 100/5 5/5 >180
11(10) 100/5 0/5 69
12(10) 100/5 2/5 >173.8
100/10 3/4 >180.0
24b(23b) 100/5 0/5 67.2
25a(23a) 100/5 0/5 95.2
a
See Ref. 5 for details of GVR35 CNS mouse model.
b
Code for parent of prodrug in parenthesis.
c
Cure defined as survival for more than 180 days after infection without showing a parasitemia relapse.
d
MSD (mean survival days) was determined for mice with and without parasitemia relapse.
e
Data from Ref. 5
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